Literature DB >> 16736122

The influence of craniofacial growth in a case of transverse facial cleft.

Antje Kirbschus1, Dietmar Gesch, Wolfram Kaduk, Tomasz Gedrange.   

Abstract

This report presents the case of a female patient bearing a right-side transverse facial cleft. She has received interdisciplinary treatment since birth. At regular intervals, dental casts were made, and profile and full-face photographs, lateral and postero-anterior cephalograms were taken during the course of orthodontic treatment and maxillofacial surgery. We evaluated her diagnostic records with the intent of documenting the effects of growth and therapy on the skeletal structures of the facial cranium and on occlusion, and to show the influence on facial esthetics. Her facial morphology and occlusion were manifest at birth and in the primary dentition. The maxilla and mandible deviated from the midsagittal plane toward the cleft side, with the mandible considerably more affected, revealing a markedly posterior position. The lateral skeletal deviation of both jaws increased slightly during growth, yet the midline deviation of the dental arches and malocclusion clearly worsened. The increasing deviation was not obvious in full-face photographs. Especially in the primary and mixed dentition, the mandible shifted to the anterior, which was visible in both the lateral cephalograms and profile photographs. On the whole, however, no noteworthy alteration in the character of the craniofacial morphology occurred by the time growth was complete, despite functional jaw-orthopedic and maxillofacial surgical treatment consisting of two distraction osteogenesis procedures.

Entities:  

Mesh:

Year:  2006        PMID: 16736122     DOI: 10.1007/s00056-006-0602-0

Source DB:  PubMed          Journal:  J Orofac Orthop        ISSN: 1434-5293            Impact factor:   1.938


  27 in total

1.  Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application.

Authors:  Vassilis E Kouloulias; John R Kouvaris; George Pissakas; Elias Mallas; Christos Antypas; John D Kokakis; George Matsopoulos; Spyros Michopoulos; Kyriaki Mystakidou; Lambros J Vlahos
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-01       Impact factor: 7.038

2.  Clinical pharmacology of famotidine.

Authors:  J L Smith
Journal:  Digestion       Date:  1985       Impact factor: 3.216

3.  Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.

Authors:  J Dunst; S Semlin; S Pigorsch; A C Müller; T Reese
Journal:  Strahlenther Onkol       Date:  2000-09       Impact factor: 3.621

4.  Histamine H(1) receptor activation inhibits the proliferation of human prostatic adenocarcinoma DU-145 cells.

Authors:  S Valencia; A Hernández-Angeles; L E Soria-Jasso; J A Arias-Montaño
Journal:  Prostate       Date:  2001-08-01       Impact factor: 4.104

5.  Radioprotective effects of cimetidine in mouse bone marrow cells exposed to gamma-rays as assayed by the micronucleus test.

Authors:  H Mozdarani; A Gharbali
Journal:  Int J Radiat Biol       Date:  1993-08       Impact factor: 2.694

Review 6.  Gastrointestinal radiation injury: prevention and treatment.

Authors:  Abobakr K Shadad; Frank J Sullivan; Joseph D Martin; Laurence J Egan
Journal:  World J Gastroenterol       Date:  2013-01-14       Impact factor: 5.742

Review 7.  Clinical pharmacology of famotidine: a summary.

Authors:  A N Chremos
Journal:  J Clin Gastroenterol       Date:  1987       Impact factor: 3.062

8.  Structural characteristics of histamine H2 receptor antagonists that scavenge hypochlorous acid.

Authors:  T L Ching; J de Jong; A Bast
Journal:  Eur J Pharmacol       Date:  1994-06-15       Impact factor: 4.432

Review 9.  Comparison of famotidine with cimetidine and ranitidine.

Authors:  R R Berardi; R M Tankanow; T T Nostrant
Journal:  Clin Pharm       Date:  1988-04

10.  H2-receptor antagonists are scavengers of oxygen radicals.

Authors:  D Lapenna; S De Gioia; A Mezzetti; L Grossi; D Festi; L Marzio; F Cuccurullo
Journal:  Eur J Clin Invest       Date:  1994-07       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.